<DOC>
	<DOCNO>NCT01620424</DOCNO>
	<brief_summary>This trial conduct Japan . The aim trial investigate pharmacokinetics pharmacodynamics biphasic insulin aspart 30 ( NN-X14Mix30 ) biphasic insulin aspart 50 ( NN-X14Mix5050 ) subject type 2 diabetes .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics Biphasic Insulin Aspart 30 50 Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 diabetes Duration diabetes least 1 year Body Mass Index ( BMI ) maximum 30.0 kg/m^2 HbA1c maximum 10.0 % Recurrent severe hypoglycaemia Proliferative preproliferative retinopathy diagnose within last 12 week laser therapy retinopathy within last 12 week Impaired hepatic function Impaired renal function Cardiac problem Uncontrolled treated / untreated hypertension Hepatitis B surface antigen , Hepatitis C antibody HIV ( human immunodeficiency virus ) antibodies positive Total daily insulin dose exceed 40 IU Treatment OHAs ( oral hypoglycaemic agent ) insulin preparation twice frequently day Treatment OHAs insulin preparation day later noon Subjects smoke 15 cigarette per day</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>